Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials. Issue 7 (July 1987)

• Record Type: Journal Article
• Authors: Amor, B; Dougados, M; Mery, C; Dardenne, M; Bach, J F
• Is Part Of: Annals of the rheumatic diseases. Volume 46:Issue 7(1987)
• Page Start: 549
• Page End: 554
• Publication Date: 1987-07
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.46.7.549
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay.